Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04902833 · ClinicalTrials.gov registry record
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
A clinical trial of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT04902833: Active study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Massachusetts General Hospital.
NCT04902833 is a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04902833, a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.
Primary Outcome
defined by PK enzyme activity or PK:HK ratio \>1 SD below the control mean (healthy subject mean) as measured by enzyme assay, or potentially pathogenic mutations in the PKLR gene as found on PKLR sequencing
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT04902833 still lists
NCT04902833 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (14% lower).
The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT04902833 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04902833 about?
NCT04902833 is a clinical study titled "Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms". This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.
What is the current status of trial NCT04902833?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2022-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04902833 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT04902833?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT04902833?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04902833 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04902833's enrollment target sits among peer trials
100 79th of 306 higher than 223 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
RECRUITING
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI